company background image
ETON logo

Eton Pharmaceuticals NasdaqGM:ETON Stock Report

Last Price

US$3.34

Market Cap

US$84.8m

7D

-6.2%

1Y

-15.7%

Updated

21 Jun, 2024

Data

Company Financials +

Eton Pharmaceuticals, Inc.

NasdaqGM:ETON Stock Report

Market Cap: US$84.8m

ETON Stock Overview

A specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.

ETON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Eton Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eton Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.34
52 Week HighUS$5.81
52 Week LowUS$2.42
Beta1.27
11 Month Change-8.74%
3 Month Change-15.66%
1 Year Change-15.66%
33 Year Change-46.30%
5 Year Change-57.72%
Change since IPO-46.56%

Recent News & Updates

Recent updates

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

FDA accepts Eton application for Topiramate for partial seizures

Dec 17

Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.

Nov 24

Shareholder Returns

ETONUS PharmaceuticalsUS Market
7D-6.2%1.0%0.5%
1Y-15.7%17.7%23.9%

Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.

Return vs Market: ETON underperformed the US Market which returned 22.9% over the past year.

Price Volatility

Is ETON's price volatile compared to industry and market?
ETON volatility
ETON Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: ETON's share price has been volatile over the past 3 months.

Volatility Over Time: ETON's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201730Sean Brynjelsenwww.etonpharma.com

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.

Eton Pharmaceuticals, Inc. Fundamentals Summary

How do Eton Pharmaceuticals's earnings and revenue compare to its market cap?
ETON fundamental statistics
Market capUS$84.78m
Earnings (TTM)US$913.00k
Revenue (TTM)US$34.30m

94.0x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ETON income statement (TTM)
RevenueUS$34.30m
Cost of RevenueUS$11.58m
Gross ProfitUS$22.72m
Other ExpensesUS$21.81m
EarningsUS$913.00k

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.036
Gross Margin66.24%
Net Profit Margin2.66%
Debt/Equity Ratio32.4%

How did ETON perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.